Related Experiment Videos
Small peripheral pulmonary adenocarcinoma: morphologic and molecular update
Jamie A Weydert1, Michael B Cohen
1Department of Pathology, The University of Iowa Carver College of Medicine, Iowa City, IA 52242-1087, USA. jamie-weydert@uiowa.edu
Advances in Anatomic Pathology
|May 2, 2007
Summary
Histopathology differentiates lung cancer into small cell and nonsmall cell types, with nonsmall cell lung carcinoma subclassification improving treatment and prognosis. Molecular and morphologic features aid in predicting responses to targeted therapies.
Area of Science:
- Oncology
- Pathology
- Molecular Biology
Background:
- Lung carcinoma is histopathologically classified into small cell lung carcinoma (SCLC) and nonsmall cell lung carcinoma (NSCLC).
- NSCLC is a heterogeneous group, necessitating further subclassification for improved patient outcomes.
- Morphologic and molecular distinctions are crucial for precise treatment and prognostication in NSCLC.
Purpose of the Study:
- To review key concepts in morphology and molecular pathology of NSCLC.
- To provide recommendations for applying these concepts in surgical pathology practice.
- To highlight the prognostic significance of specific histomorphologic features and molecular markers.
Main Methods:
- Review of histomorphologic features associated with good prognosis in peripheral adenocarcinomas.
- Analysis of molecular markers, including epidermal growth factor receptor (EGFR) mutations and gene copy number.
- Correlation of histopathology and molecular findings with clinical outcomes and treatment response.
Main Results:
- Pure bronchioloalveolar carcinoma, minimal invasion, and minimal scarring in lepidic growth patterns indicate a good prognosis.
- Activating EGFR mutations and increased EGFR gene copy number predict responsiveness to tyrosine kinase inhibitors in lung adenocarcinoma.
- Subclassification of NSCLC based on morphology and molecular pathology offers promise for tailored treatments.
Conclusions:
- Morphologic assessment and molecular profiling are essential for accurate NSCLC diagnosis and patient management.
- Integration of these findings into surgical pathology practice can enhance treatment strategies and prognostication.
- Understanding NSCLC heterogeneity is key to advancing personalized medicine in lung cancer treatment.